Date published: 2025-10-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

Nifedipine (CAS 21829-25-4)

5.0(1)
Write a reviewAsk a question

See product citations (15)

Alternate Names:
Procardia; L-Type Calcium Channel Blocker III
Application:
Nifedipine is a selective calcium channel protein inhibitor
CAS Number:
21829-25-4
Purity:
≥98%
Molecular Weight:
346.33
Molecular Formula:
C17H18N2O6
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Nifedipine is a selective hypertensive calcium channel protein inhibitor which targets L-type voltage-sensitive calcium channels. Nifedipine is a vasodilator that is selective for inotropic over chronotropic cardiac effects. It has also been shown to induce apoptosis in human glioblastoma cells and inhibit advanced glycation end product-induced mesangial cell damage in vitro. Additionally, nifedipine has been suggested to work as an antioxidant and antiinflammatory agent against AGEs in tubular cells by suppressing RAGE expression via PPAR-gamma activation.


Nifedipine (CAS 21829-25-4) References

  1. Effect of calcium channel antagonists nifedipine and nicardipine on rat cytochrome P-450 2B and 3A forms.  |  Zangar, RC., et al. 1999. J Pharmacol Exp Ther. 290: 1436-41. PMID: 10454523
  2. Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats.  |  Eliot, LA. and Jamali, F. 1999. J Pharmacol Exp Ther. 291: 188-93. PMID: 10490903
  3. Cardiac inotropic vs. chronotropic selectivity of isradipine, nifedipine and clevidipine, a new ultrashort-acting dihydropyridine.  |  Segawa, D., et al. 1999. Eur J Pharmacol. 380: 123-8. PMID: 10513571
  4. Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation.  |  Matsui, T., et al. 2010. Biochem Biophys Res Commun. 398: 326-30. PMID: 20599709
  5. Biopolymeric nifedipine powder for acceleration of wound healing.  |  Samy, W., et al. 2012. Int J Pharm. 422: 323-31. PMID: 22119966
  6. Atosiban and nifedipine in the suppression of pre-term labour: a comparative study.  |  Saleh, SS., et al. 2013. J Obstet Gynaecol. 33: 43-5. PMID: 23259877
  7. Modelling nifedipine photodegradation, photostability and actinometric properties.  |  Maafi, W. and Maafi, M. 2013. Int J Pharm. 456: 153-64. PMID: 23954300
  8. Calcium antagonism and calcium entry blockade.  |  Godfraind, T., et al. 1986. Pharmacol Rev. 38: 321-416. PMID: 2432624
  9. Multiple calcium channels and neuronal function.  |  Miller, RJ. 1987. Science. 235: 46-52. PMID: 2432656
  10. Role of kaempferol to increase bioavailability and pharmacokinetics of nifedipine in rats.  |  Park, JW. and Choi, JS. 2019. Chin J Nat Med. 17: 690-697. PMID: 31526504
  11. Calcium Channel Blocker Nifedipine Suppresses Colorectal Cancer Progression and Immune Escape by Preventing NFAT2 Nuclear Translocation.  |  Wu, L., et al. 2020. Cell Rep. 33: 108327. PMID: 33113363
  12. Chronopharmacology of the alpha-lipoic acid/nifedipine/glimepiride combination in the amelioration of retinopathy in rats.  |  Oraebosi, MI., et al. 2021. Chronobiol Int. 38: 443-450. PMID: 33356611
  13. Diurnal efficacy of alpha-lipoic acid/nifedipine/glimepiride combination mitigates diabetic neuropathies in rats.  |  Oraebosi, MI., et al. 2022. Ann Pharm Fr. 80: 291-300. PMID: 34599891
  14. Dissolution Kinetics of Nifedipine-Ionizable Polymer Amorphous Solid Dispersion: Comparison Between Bicarbonate and Phosphate Buffers.  |  Sakamoto, A. and Sugano, K. 2021. Pharm Res. 38: 2119-2127. PMID: 34931285
  15. Polyvinylpyrrolidone as co-inhibitor of crystallization of nifedipine in paper tablets.  |  Heidrich, L., et al. 2023. Int J Pharm. 635: 122721. PMID: 36781082

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Nifedipine, 1 g

sc-3589
1 g
$58.00

Nifedipine, 5 g

sc-3589A
5 g
$170.00